Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of an Immuno-radiomic Signature on Intracranial Treatment Efficacy in Non-small Cell Lung Cancer With Brain Metastases at Diagnosis

NCT07904013 is registered in ClinicalTrials.gov with University Hospital, Bordeaux as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07904013 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of an Immuno-radiomic Signature on Intracranial Treatment Efficacy in Non-small Cell Lung Cancer With Brain Metastases at Diagnosis
Lead sponsor
University Hospital, Bordeaux
Phase
Observational
Overall status
Not yet recruiting
Start date
December 31, 2026
Completion date
December 31, 2028
Enrollment
38 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

Arms

As registered; 1 arm.

  • Patients with brain metastases from NSCLC Radiomic analysis; Bulk RNA sequencing

    Patients aged 18 years or older with advanced or metastatic non-small cell lung cancer, at least one resected brain metastasis at diagnosis, and an indication for first-line immunotherapy plus chemotherapy

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Correlation between MRI-based radiomic signature and transcriptomic signature of brain metastases At diagnosis, before treatment initiation

    Correlation between quantitative radiomic features extracted from brain MRI and transcriptomic profiles obtained from bulk RNA sequencing of resected brain metastasis tissue

Lead sponsor's other trials

University Hospital, Bordeaux, most recent start first.

Similar trials

Same condition (Brain Neoplasms) and phase, most recent start first.